CLOs on the Move

Click Therapeutics

www.clicktherapeutics.com

 
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click is also progressing a broad pipeline of prescription Digital Therapeutics across a variety of high-burden therapeutic areas, including Major Depressive ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Advanced Environmental Testing And Abatement

Advanced Environmental Testing And Abatement is a Waterloo, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

La Casa Assisted Living

La Casa Assisted Living is a Merritt Island, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TriSalus Life Sciences

TriSalus Life Sciences is dedicated to improving patient outcomes in pancreatic and other highly intractable solid tumors. TriSalus Infusion Systems, powered by the proprietary Pressure-Enabled Drug Delivery (PEDD) approach with SmartValve technology have the potential to improve the delivery and distribution of diagnostic agents, therapeutics, and immuno-stimulants into the tumor vasculature.

TYME Inc

TYME is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.

Adicet Bio

Adicet Bio, Inc. is a publicly held biotechnology company (Nasdaq: ACET) discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.